This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Study Type
OBSERVATIONAL
Enrollment
403
Overall survival
Time frame: 2 years
Progression-free survival
Time frame: 2 years
Best Overall Response Rate (BORR)
Time frame: 2 years
Time to response
Time frame: 2 years
Duration of response
Time frame: 2 years
ECOG performance status
Time frame: 2 years
Safety: Incidence of adverse events
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
Chieti, Abruzzo, Italy
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
Bari, Apulia, Italy
IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative
Napoli, Campania, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
Bologna, Emilia-Romagna, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST);U.O. di Immunoterapia
Meldola, Emilia-Romagna, Italy
Arcispedale Santa Maria Nuova; Oncologia
Reggio Emilia, Emilia-Romagna, Italy
Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica
Rome, Lazio, Italy
Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche
Rome, Lazio, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
Genoa, Liguria, Italy
Asst Papa Giovanni XXIII; Oncologia Medica
Bergamo, Lombardy, Italy
...and 14 more locations